Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular and Clinical Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 2049-9450 Online ISSN: 2049-9469
Journal Cover
April-2018 Volume 8 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
April-2018 Volume 8 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate

  • Authors:
    • Masato Yasui
    • Yoriko Hasegawa
    • Takashi Kawahara
    • Yohei Kumano
    • Yasuhide Miyoshi
    • Nobuaki Matsubara
    • Hiroji Uemura
  • View Affiliations / Copyright

    Affiliations: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama 232-0024, Japan, Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa 277‑8577, Japan
  • Pages: 587-591
    |
    Published online on: February 13, 2018
       https://doi.org/10.3892/mco.2018.1573
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Abiraterone acetate (AA), a CYP17 inhibitor, now has a crucial role in the treatment of castration-resistant prostate cancer (CRPC), and previous studies have reported several prognostic clinical factors for AA treatment. The neutrophil‑to‑lymphocyte ratio (NLR) has also been investigated for a CRPC treatments in a few reports, however it has not been identified to be a prognostic factor for AA treatment in Japanese patients. The present study aimed to assess the association of the baseline NLR with the overall survival (OS) in CPRC patients treated by AA. The present study retrospectively reviewed a total of 90 consecutive patients with CRPC treated with AA from 2011 to 2016 at Yokohama City University Medical Center and National Cancer Center Hospital East. The primary endpoint of the study was the OS, which was defined as the survival from the start of AA administration. The secondary endpoint was the prostate‑specific antigen (PSA) response. PSA response was defined as a reduction in antigen levels of >50%. Complete blood cell counts were performed, and the NLR was calculated using the neutrophil and lymphocyte counts obtained on the same day or a few days prior to the initiation of AA therapy. The NLR cut‑off point was determined to be 3.76 for the OS, and divided into the high NLR group of 34 patients and the low NLR group of 56 patients. A PSA response was obtained in 8 patients (23.5%) in the high NLR group and in 24 (42.9%) in the low NLR group. The difference of PSA response between the two groups was significant (P=0.037). Kaplan‑Meier curves demonstrated that a high NLR [NLR ≥3.76; median OS: 8.4 months; 95% confidence interval (CI): 6.325‑10.475 months] was correlated with a risk of mortality compared with a low NLR (NLR <3.76; median OS not reached). A multivariate analysis demonstrated that the NLR was an independent predictor for the OS (hazard ratio: 2.682; 95% CI: 1.143‑6.293; P=0.023). The findings suggest that the NLR may be a useful novel biomarker for predicting the prognosis of CRPC patients treated with AA.
View Figures

Figure 1

Figure 2

Figure 3

View References

1 

Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, Valero V and Hortobagyi GN: Squamous cell carcinoma of the breast. J Clin Oncol. 23:7827–7835. 2005. View Article : Google Scholar : PubMed/NCBI

2 

Tavassoli FA and Devilee P: Metaplastic carcinomasPathology and Genetics. Tumours of the Breast and Female Genital Organs. World Organization Classification of Tumors. IARC Press; Lyon: pp. 37–38. 2003

3 

Rosen PR: Chapter 21. Rosen's Breast Pathology. Lippincott-Raven; Philadelphia, New York: pp. 397–404. 1997

4 

Leboit PE, Burg G, Weedon D and Sarasin A: Squamous Cell CarcinomaPathology and Genetics. Skin Tumors. World Organization Classification of Tumors. IARC Press; Lyon: pp. 20–21. 2007

5 

Miranda BH, Malahias M, El-Said TF and Fahmy FS: Axillary skin malignancy: A rare breast cancer presentation. Ann Plast Surg. 72:513–514. 2014. View Article : Google Scholar : PubMed/NCBI

6 

Badge SA, Gangane NM, Shivkumar VB and Sharma SM: Primary squamous cell carcinoma of the breast. Int J Appl Basic Med Res. 4:53–55. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Mitra B, Pal M, Debnath S, Paul B, Saha TN and Maiti A: Primary squamous cell carcinoma of breast with ipsilateral axillary lymph node metastasis: An unusual case. Int J Surg Case Rep. 2:194–197. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Flikweert ER, Hofstee M and Liem MS: Squamous cell carcinoma of the breast: A case report. World J Surg Oncol. 6:1352008. View Article : Google Scholar : PubMed/NCBI

9 

Tsung SH: Primary pure squamous cell carcinoma of the breast might be sensitive to Cisplatin-based chemotherapy. Case Rep Oncol. 5:561–565. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Bhosale SJ, Kshirsagar AY, Deshmukh SJ, Jagtap SV and Langade YB: Squamous cell carcinoma of the breast. Am J Case Rep. 14:188–190. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Wang J, Zhang X, He J, Yang M, Tang J, Li X, Tang H and Xie X: Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast. Med Oncol. 31:1722014. View Article : Google Scholar : PubMed/NCBI

12 

Porzio R, Cordini C, Orsi N, Brigati F, Paties CT and Cavanna L: Primary squamous cell carcinoma of the breast after cured bilateral breast cancer. In Vivo. 28:1155–1158. 2014.PubMed/NCBI

13 

Mokhtar GA: Squamous cell carcinoma of the breast. Saudi Med J. 30:1346–1349. 2009.PubMed/NCBI

14 

Sharma R, Usmani S and Siegel R: Primary squamous cell carcinoma of breast in background of phyllodes tumor-a case report. Conn Med. 73:341–343. 2009.PubMed/NCBI

15 

Cichon P, Drucis K and Piotrkowski J: Primary squamous cell carcinoma of the breast-a case report. Pol Merkur Lekarski. 38:140–143. 2015.(In Polish). PubMed/NCBI

16 

Samuels TH, Miller NA, Manchul LA, DeFreitas G and Panzarella T: Squamous cell carcinoma of the breast. Can Assoc Radiol J. 47:177–182. 1996.PubMed/NCBI

17 

Salemis NS: Breast abscess as the initial manifestation of primary pure squamous cell carcinoma: A rare presentation and literature review. Breast Dis. 33:125–131. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Nair VJ, Kaushal V and Atri R: Pure squamous cell carcinoma of the breast presenting as a pyogenic abscess: A case report. Clin Breast Cancer. 7:713–715. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Liu J, Yu Y, Sun JY, He SS, Wang X, Yin J and Cao XC: Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Cancer Res Treat. 149:133–140. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Behranwala KA, Nasiri N, Abdullah N, Trott PA and Gui GP: Squamous cell carcinoma of the breast: Clinico-pathologic implications and outcome. Eur J Surg Oncol. 29:386–389. 2003. View Article : Google Scholar : PubMed/NCBI

21 

Shui R, Li A, Yang F, Zhou X, Yu B, Xu X and Yang W: Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype. Int J Clin Exp Pathol. 7:5203–5209. 2014.PubMed/NCBI

22 

Lebbe C, Becker JC, Grob JJ, Malvehy J, Del Marmol V, Pehamberger H, Peris K, Saiag P, Middleton MR, Bastholt L, et al: Diagnosis and treatment of merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 51:2396–2403. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Kurpad V, Prabhu KC, Ramesh MK and Harindranath HR: Primary denovo squamous cell carcinoma breast masquerading as breast abscess. Indian J Surg Oncol. 4:48–51. 2013. View Article : Google Scholar : PubMed/NCBI

24 

Murialdo R, Boy D, Musizzano Y, Tixi L, Murelli F and Ballestrero A: Squamous cell carcinoma of the breast: A case report. Cases J. 2:73362009.PubMed/NCBI

25 

Rowe DE, Carroll RJ and Day CL Jr: Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 26:976–990. 1992. View Article : Google Scholar : PubMed/NCBI

26 

Schmults CD, Karia PS, Carter JB, Han J and Qureshi AA: Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: A 10-year, single-institution cohort study. JAMA Dermatol. 149:541–547. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Nayak A, Wu Y and Gilcrease MZ: Primary squamous cell carcinoma of the breast: Predictors of locoregional recurrence and overall survival. Am J Surg Pathol. 37:867–873. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Yasui M, Hasegawa Y, Kawahara T, Kumano Y, Miyoshi Y, Matsubara N and Uemura H: Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate. Mol Clin Oncol 8: 587-591, 2018.
APA
Yasui, M., Hasegawa, Y., Kawahara, T., Kumano, Y., Miyoshi, Y., Matsubara, N., & Uemura, H. (2018). Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate. Molecular and Clinical Oncology, 8, 587-591. https://doi.org/10.3892/mco.2018.1573
MLA
Yasui, M., Hasegawa, Y., Kawahara, T., Kumano, Y., Miyoshi, Y., Matsubara, N., Uemura, H."Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate". Molecular and Clinical Oncology 8.4 (2018): 587-591.
Chicago
Yasui, M., Hasegawa, Y., Kawahara, T., Kumano, Y., Miyoshi, Y., Matsubara, N., Uemura, H."Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate". Molecular and Clinical Oncology 8, no. 4 (2018): 587-591. https://doi.org/10.3892/mco.2018.1573
Copy and paste a formatted citation
x
Spandidos Publications style
Yasui M, Hasegawa Y, Kawahara T, Kumano Y, Miyoshi Y, Matsubara N and Uemura H: Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate. Mol Clin Oncol 8: 587-591, 2018.
APA
Yasui, M., Hasegawa, Y., Kawahara, T., Kumano, Y., Miyoshi, Y., Matsubara, N., & Uemura, H. (2018). Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate. Molecular and Clinical Oncology, 8, 587-591. https://doi.org/10.3892/mco.2018.1573
MLA
Yasui, M., Hasegawa, Y., Kawahara, T., Kumano, Y., Miyoshi, Y., Matsubara, N., Uemura, H."Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate". Molecular and Clinical Oncology 8.4 (2018): 587-591.
Chicago
Yasui, M., Hasegawa, Y., Kawahara, T., Kumano, Y., Miyoshi, Y., Matsubara, N., Uemura, H."Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate". Molecular and Clinical Oncology 8, no. 4 (2018): 587-591. https://doi.org/10.3892/mco.2018.1573
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team